Tempus AI Stock Drops 11.22% in Three Days Despite Strategic Partnership with Verastem Oncology Ranking 56th in Daily Trading Volume

On May 21, 2025, Tempus AI (TEM) experienced a significant decline, dropping by 6.87% and marking its third consecutive day of losses, with a total decrease of 11.22% over the past three days. The trading volume for Tempus AI reached 12.18 billion, placing it at the 56th position in the daily stock market rankings.

Tempus AI, Inc. has announced a strategic collaboration with Verastem Oncology to develop a companion diagnostic (CDx) test. This partnership aims to create a diagnostic tool for the first-ever FDA-approved KRAS-mutant recurrent low-grade serous ovarian cancer combination treatment. The collaboration is expected to enhance the precision and effectiveness of cancer treatments, potentially driving long-term growth for Tempus AI.

Tempus AI's recent partnership with Verastem Oncology is a significant development that could positively impact its stock performance. The collaboration focuses on developing a companion diagnostic test for recurrent low-grade serous ovarian cancer, which has recently received FDA approval. This strategic move aligns with Tempus AI's mission to leverage advanced technology for precision medicine, potentially attracting more investors and boosting market confidence.